Substance Use Disorder Diagnosis: Criteria and Clinical Process

Substance use disorder (SUD) diagnosis is the formal clinical process by which licensed professionals determine whether a pattern of substance use meets established psychiatric and medical criteria. This page covers the diagnostic framework established by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the role of clinician-administered assessments, the distinction between severity levels, and the clinical boundaries that separate a diagnosable disorder from other patterns of use. Accurate diagnosis directly shapes the levels of care and treatment planning a patient receives.

Definition and scope

Substance use disorder, as defined by the American Psychiatric Association (APA) in the DSM-5, is a cluster of cognitive, behavioral, and physiological symptoms indicating that an individual continues using a substance despite significant substance-related problems. The DSM-5, published in 2013 and updated in the DSM-5-TR (2022), replaced the prior binary of "abuse" and "dependence" with a single dimensional spectrum running from mild to severe, classified by the number of diagnostic criteria met (APA DSM-5-TR).

The DSM-5 framework covers 10 substance classes, including alcohol, cannabis, opioids, stimulants, sedatives/hypnotics/anxiolytics, and hallucinogens, among others. Each class maps to the same 11 diagnostic criteria. Diagnosis applies across all age groups, though clinicians reference the DSM-5's guidance on developmental considerations when assessing adolescents — a population covered by distinct program structures described in the adolescent drug rehab programs reference.

The Substance Abuse and Mental Health Services Administration (SAMHSA) frames SUD as a recognized public health condition governed under federal law, including the Mental Health Parity and Addiction Equity Act (MHPAEA) and the Affordable Care Act (ACA), both of which mandate coverage parity for SUD treatment in qualifying health plans (SAMHSA).

How it works

Clinical SUD diagnosis proceeds through a structured sequence:

1. Screening — Brief validated instruments identify risk. Commonly used tools include the AUDIT (Alcohol Use Disorders Identification Test, developed by the World Health Organization) for alcohol, and the DAST-10 (Drug Abuse Screening Test) for other substances. Screening is not diagnostic; it triggers further evaluation.

2. Comprehensive assessment — A licensed clinician — typically a physician, psychologist, or licensed clinical social worker — conducts a structured clinical interview. The interview covers substance use history, frequency, quantity, and context; medical and psychiatric history; and psychosocial functioning.

3. DSM-5 criteria application — The clinician maps reported symptoms to the DSM-5's 11 criteria, organized into four domains:

4. Impaired control (criteria 1–4): taking more than intended, failed efforts to cut down, significant time spent, craving
5. Social impairment (criteria 5–7): failure to fulfill obligations, continued use despite interpersonal problems, reduction of important activities
6. Risky use (criteria 8–9): use in hazardous situations, continued use despite physical or psychological harm

7. Pharmacological criteria (criteria 10–11): tolerance and withdrawal

8. Severity classification — The count of criteria met determines severity: 2–3 criteria = mild SUD; 4–5 criteria = moderate SUD; 6 or more criteria = severe SUD (APA DSM-5-TR, §Substance-Related Disorders).

9. Differential diagnosis — Clinicians rule out substance-induced disorders (e.g., substance-induced psychosis) that mimic primary psychiatric conditions, as well as medical etiologies. Co-occurring disorders — independent psychiatric diagnoses alongside SUD — are identified separately and require integrated treatment planning.

10. Documentation and care coordination — Findings are recorded in clinical records, subject to confidentiality protections under 42 CFR Part 2 (federal SUD record confidentiality regulations) and HIPAA. Details on those protections are covered in the HIPAA confidentiality in rehab reference.

Common scenarios

Alcohol use disorder (AUD) is the most frequently diagnosed SUD in the United States. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) estimates approximately 29.5 million people aged 12 and older met criteria for AUD in 2021 (NIAAA 2022 Survey on Drug Use and Health). Clinicians assess AUD using the same 11 DSM-5 criteria with particular attention to withdrawal severity, since alcohol withdrawal carries seizure risk — a factor that influences whether detox services are medically necessary.

Opioid use disorder (OUD) diagnosis is clinically significant because it unlocks access to FDA-approved medications, including buprenorphine, methadone, and naltrexone, under the framework of medication-assisted treatment. SAMHSA regulates opioid treatment programs (OTPs) under 42 CFR Part 8, requiring OUD diagnosis as a prerequisite for methadone dispensing.

Stimulant use disorder and sedative, hypnotic, or anxiolytic use disorder follow the same 11-criterion model but present distinct withdrawal profiles — stimulant withdrawal features depressed mood and hypersomnia, while benzodiazepine withdrawal can include life-threatening seizures, analogous to alcohol.

Decision boundaries

A critical clinical distinction lies between substance use disorder and substance use without disorder. Substance use — even hazardous use — that meets fewer than 2 DSM-5 criteria does not qualify as a diagnosable disorder. This boundary matters for insurance coverage determinations, treatment level authorization, and legal contexts.

A second boundary separates physical dependence from SUD. Physical dependence — manifested as tolerance and withdrawal — can occur with prescribed medications (e.g., opioids for chronic pain, benzodiazepines for anxiety) without meeting the broader behavioral and functional criteria for SUD. DSM-5 explicitly notes that tolerance and withdrawal alone, when occurring solely from medically supervised use, do not constitute SUD (APA DSM-5-TR, §Substance-Related Disorders, Diagnostic Criteria Notes).

The American Society of Addiction Medicine (ASAM) Patient Placement Criteria (ASAM Criteria, 4th Edition) operationalize diagnosis into placement decisions across six assessment dimensions — including intoxication/withdrawal potential, biomedical conditions, emotional/behavioral conditions, readiness to change, relapse potential, and recovery environment. ASAM Criteria serve as the primary placement tool used by insurers and treatment programs nationally (ASAM).

Clinicians must also distinguish SUD from substance-induced disorders — transient psychiatric symptoms (psychosis, depression, anxiety) caused directly by substance intoxication or withdrawal that resolve with abstinence, as opposed to independent co-occurring disorders requiring parallel psychiatric treatment.

References

• American Psychiatric Association — DSM-5-TR
• Substance Abuse and Mental Health Services Administration (SAMHSA)
• National Institute on Alcohol Abuse and Alcoholism (NIAAA) — Alcohol Facts and Statistics
• American Society of Addiction Medicine (ASAM) — ASAM Criteria
• SAMHSA — 42 CFR Part 8, Opioid Treatment Program Regulations
• U.S. Department of Health and Human Services — 42 CFR Part 2 Confidentiality Regulations
• World Health Organization — AUDIT Screening Tool